Early Testing of Alzheimer's using Biomarkers
DOI:
https://doi.org/10.47611/jsrhs.v11i4.3670Keywords:
Alzheimers, Biomarkers, Early TestingAbstract
This paper covers the biomarkers that can be used to test for and diagnose Alzheimer’s Disease. This is important due to the large number of people globally who are suffering from this disease. Two types of biomarker origins were explored here: blood and cerebrospinal fluid. Currently, the standard for testing Alzheimer’s biomarkers is through the use of cerebrospinal fluid collection. These are the biomarkers that have been thoroughly tested and accepted as accurate and reliable, such as Aβ (1-42) and Tau-related proteins. There are also possible biomarkers found in blood. These include Aβ-related proteins, Tau-related enzymes, as well as inflammatory markers. It has been concluded that the most reliable source of biomarker testing is cerebrospinal fluid. However, there have been significant advancements in studies showing that the use of blood may one day become a very real possibility for routine testing. Until then, it is best to keep a healthy lifestyle that will aid in the prevention of this disease.
Downloads
References or Bibliography
Counts, S. C., Ikonomovic, M. I., Mercado, N. M., Vega, I. V., & Mufson, E. M. (2016). Biomarkers for the Early Detection and Progression of Alzheimer’s Disease. Neurotherapeutics, 14, 35–53. https://doi.org/10.1007/s13311-016-0481-z
Humpel, C. H. (2011). Identifying and validating biomarkers for Alzheimer’s disease. Trends in Biotechnology, 29(1), 26–32. https://doi.org/10.1016/j.tibtech.2010.09.007.
Mattsson, N. M., Brax, D. B., & Zetterberg, H. Z. (2010). To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer’s Disease. International Journal of Alzheimer’s Disease. https://doi.org/10.4061/2010/841941
Milà-Alomà, M. M., Suárez-Calvet, M. S., & Molinuevo, J. M. (2019). Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Therapeutic Advances in Neurological Disorders, 12. https://doi.org/10.1177/1756286419888819
Schneider, P. S., Hampel, H. H., & Buerger, K. B. (2009). Biological Marker Candidates of Alzheimer’s Disease in Blood, Plasma, and Serum. CNS Neuroscience & Therapeutics, 15, 358–374. https://doi.org/10.1111/j.1755-5949.2009.00104.x
Sindi, S. S., Mangialasche, F. M., & Kivipelto, M. K. (2015). Advances in the prevention of Alzheimer’s Disease. F1000 Prime Reports, 7(50). https://doi.org/10.12703/P7-50
Sjögren, M. S. (2001). Both total and phosphorylated tau are increased in Alzheimer’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 70(5). http://dx.doi.org/10.1136/jnnp.70.5.624
Strimbu, K. S., & Tavel, J. T. (2010). What are Biomarkers? Current Opinion in HIV and AIDS, 5(6), 463–466. https://doi.org/10.1097/COH.0b013e32833ed177
Published
How to Cite
Issue
Section
Copyright (c) 2022 Kiranpreet Utal; Jothsna Kethar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
